Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH).

Our multi-modal investigational drug, efruxifermin (EFX), is designed to treat MASH holistically. EFX has been engineered to mimic the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes.

Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH).

Akero Therapeutics is a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program efruxifermin (EFX) to provide a powerful new treatment for patients with MASH, a disease for which there are few effective treatment options.

2025年2月28日 · Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH).

2025年1月27日 · Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send its stock up about...

3 天之前 · Akero's SYMMETRY is the only study to show histologic reversal of cirrhosis (F4) in a meaningful proportion of patients (39%) with placebo control — making it a standout result in the MASH space.

Student media plans with precise targeting and customized recommendations, powered by billions of data points, with live reporting on every metric that matters. Create next gen forms instantly, build stunning landing pages with the drag and drop builder, and increase inquiries by up to 5x.

Akero is a clinical-stage company developing transformational medicines for people with serious metablic diseases such as MASH.